Drug Profile
Tanezumab - Eli Lilly and Company/Pfizer
Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Rinat Neuroscience
- Developer Eli Lilly and Company; Pfizer
- Class Monoclonal antibodies; Non-opioid analgesics
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Back pain; Musculoskeletal pain
- Suspended Diabetic neuropathies
- No development reported Postherpetic neuralgia
- Discontinued Cancer pain
Most Recent Events
- 05 Jan 2022 Adverse events data of a phase III OA SAFETY STUDY in patients with Osteoarthritis (OA) presented at ACR Convergence 2021 (ACR/ARP-2021)
- 05 Jan 2022 Pooled adverse events data from phase III trials in Osteoarthritis presented at ACR Convergence 2021 (ACR/ARP-2021)
- 05 Nov 2021 Pooled efficacy data from two phase III trials in Osteoarthritis presented at the ACR Convergence 2021 (ACR/ARP-2021)